{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-003516","form_type":"8-K","ticker":"PMDI","cik":"0000806517","company_name":"PSYCHEMEDICS CORP","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.773261+00:00","generated_at":"2026-06-25T22:06:00.938751+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Psychemedics Q1 revenue up 14% to $6.5M; declares increased dividend of $0.07/share","bullets":["Revenue $6.5M vs $5.7M (+14% YoY); domestic revenue up 17%, international down 42%.","Net income $39k ($0.01 diluted EPS) vs $83k; prior year included $800k ERC benefit.","Declares cash dividend of $0.07/share, payable June 24, 2022, to holders of record May 27, 2022.","Cash $2.1M, working capital $5.2M; equipment financing $1.1M, repaid $11.1M since May 2014.","Strategic alternatives review ongoing; CEO cites momentum in oil/gas, transport, and manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-003516","json":"https://secwatch.observer/filing/0001171843-22-003516.json","markdown":"https://secwatch.observer/filing/0001171843-22-003516.md","text":"https://secwatch.observer/filing/0001171843-22-003516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/806517/000117184322003516/0001171843-22-003516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/806517/000117184322003516/f8k_051022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:06:00.938751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}